Pseudonormal mitral filling pattern predicts hospital re-admission in patients with congestive heart failure  by Whalley, Gillian A et al.
Pseudonormal Mitral Filling Pattern
Predicts Hospital Re-Admission in
Patients With Congestive Heart Failure
Gillian A. Whalley, MHSC, Robert N. Doughty, MB BS, MRCP, FRACP, MD, Greg D. Gamble, MSC,
Susan P. Wright, MBCHB, MMEDSC, Helen J. Walsh, RN, BSC, Stephanie A. Muncaster, RN,
Norman Sharpe, MD, FRACP, FACC
Auckland, New Zealand
OBJECTIVES We sought to investigate whether pseudonormal (PN) filling was associated with death or
hospital admission in patients with congestive heart failure (CHF).
BACKGROUND The high mortality rate associated with CHF is related to many clinical and echocardio-
graphic variables. In particular, a short mitral deceleration time and restrictive diastolic filling
predict death and/or hospital admission. We hypothesized that differentiating patients with
nonrestrictive filling might identify an intermediate PN group that may be associated with
intermediate risk.
METHODS A total of 115 patients admitted to the hospital for exacerbation of CHF symptoms
underwent pre-discharge Doppler echocardiography to determine mitral inflow (before and
after preload reduction) and pulmonary venous return. Patients were followed up for one year,
and all-cause mortality and re-admission data were analyzed.
RESULTS The classification of filling patterns was: abnormal relaxation (AR) in 46 (40%) patients,
pseudonormal (PN) filling in 42 (36.5%) patients and restrictive filling pattern (RFP) in 27
(23.4%) patients. When comparing the RFP group with the AR group, all-cause mortality
was higher (38.4% vs. 17.4%, p  0.033), hospital admission was higher (70.3% vs. 54.3%,
p  0.073), death/hospital admission was higher (77.8% vs. 56.5%, p  0.02), CHF hospital
admission was higher (40.7% vs. 15.2%, p  0.01) and death/CHF hospital admission was
higher (62.9% vs. 26.1%, p  0.0005). Mortality in the PN group was not significantly
different from that in the two other groups, but re-admissions were higher than the AR group
(76.2% vs. 54.3%, p  0.006), as was death/re-admission (78.6% vs. 56.5%, p  0.004) and
death/CHF re-admission (47.6% vs. 26.1%, p  0.03). Re-admissions in the PN and RFP
groups were comparable.
CONCLUSIONS In a general hospital population of older patients with CHF, PN filling was associated with
hospital admission rates similar to those seen with restrictive filling. The combined end point
of death/CHF hospital admission was similar for restrictive filling and AR. Measurement of
these variables is easy to add to routine clinical echocardiography and may provide important
prognostic information in a wide range of patients with CHF. (J Am Coll Cardiol 2002;39:
1787–95) © 2002 by the American College of Cardiology Foundation
Despite optimal medical therapy, mortality associated with
congestive heart failure (CHF) remains high (1,2). Several
clinical and functional variables predict survival, including
New York Heart Association (NYHA) functional class (3),
peak oxygen uptake (4,5) end-systolic volume (6), ejection
fraction (EF) (3,4,7), creatinine clearance (8) and echo-
Doppler indexes of diastolic filling (9–13).
See page 1796
Pulsed wave Doppler (PWD) assessment of the mitral
valve is routinely used in clinical practice to assess left
ventricular (LV) diastolic filling noninvasively. Five pro-
gressive filling categories have been described: normal,
abnormal relaxation (AR), pseudonormal (PN), reversible
restrictive filling and nonreversible restrictive filling, based
on early (E) and late (A) peak filling velocities and E-wave
deceleration time (DT) (14–17). On its own, mitral PWD
does not permit differentiation between true normal and PN
filling patterns. Pulmonary venous PWD, when used in
conjunction with mitral inflow, helps to differentiate be-
tween true normal and PN filling and is useful for estimat-
ing left atrial (LA) pressure (16,18–21). However, trans-
thoracic pulmonary venous Doppler recordings are
frequently suboptimal (22), and other methods are required.
A preload reduction, achieved with the Valsalva maneuver
or sublingual glyceryl trinitrate, can assist in the differenti-
ation between PN and true normal patterns (16,23,24) and
can also differentiate reversible from nonreversible restrictive
filling.
Differentiating a restrictive filling pattern (RFP) from a
non-RFP provides important independent prognostic infor-
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mation (9–13). When RFP is further categorized into
reversible (responsive to pharmacologic preload reduction)
or nonreversible (unresponsive), the latter is associated with
a worse outcome (25–27). Peak oxygen uptake is also
reduced in patients with CHF who have RFP (28), and the
combination of RFP and reduced peak oxygen uptake
provides additional prognostic information (10).
Recently, in patients with a first myocardial infarction
and normal systolic function, the presence of PN filling
within 24 h of the myocardial infarction predicted cardiac
death and LV dilation (29). The effect fell between that
observed for patients with RFP and AR. Similarly, a short
DT is associated with adverse remodeling (30) and the
development of CHF after infarction (31,32). The presence
of RFP is the single best predictor of cardiac death (33).
We hypothesized that intermediate PN filling would
provide additional prognostic information in patients with
CHF, beyond the simple classification of non-RFP or RFP,
which most studies have used. Thus, the aim of this study
was to investigate whether the distinction of different
patient groups, based on filling patterns, was associated with
survival or re-admission in a chronic heart failure popula-
tion.
METHODS
Study group. Patients included were those enrolled in a
randomized, controlled trial of integrated heart failure
management, carried out at our institution between 1996
and 1999 (34). The intervention had a beneficial effect on
multiple re-admission rates, bed days and quality of life, but
not on mortality (34). All patients admitted to the general
medical wards at Auckland Hospital with a primary diag-
nosis of CHF were eligible. Exclusion criteria were: 1) a
surgically remediable cause of heart failure, such as severe
valve disease; 2) consideration for transplantation; 3) the
inability to provide informed consent; 4) terminal cancer;
and 5) participation in any other clinical trial. For the
current analyses, only patients in sinus rhythm at the
baseline echocardiographic examination were included.
Congestive heart failure was diagnosed on the basis of
typical symptoms and signs, with a review of the chest
radiograph, electrocardiogram (ECG) and echocardiogram.
The Auckland Ethics Committee approved the study, and
written, informed consent was obtained from each patient
during the index hospital admission. Details of the patients’
clinical history, physical examination, blood biochemistry
results and ECG and chest radiographic findings were
recorded before discharge.
The primary end points for this report were all-cause
mortality, hospital admission and a combined end point of
mortality and first hospital admission at one year. Outcome
data were collected from the hospital records, primary care
records and death certificates.
Echocardiographic methods. All patients were examined
while lying on their left side, and images were obtained
according to a standard protocol, using one of two ultra-
sound machines (ATL HDI-3000, ATL Ultrasound, Both-
ell, Washington or Acuson XP128, Acuson Corp., Moun-
tainview, California). Images were recorded onto videotape
and digitally acquired for off-line analysis (NovaMicroson-
ics, Kodak Eastman, Allendale, New Jersey). Mitral valve
PWD recordings were obtained from the apical four-
chamber view with a 5-mm PWD sample volume placed
distal (5 to 10 mm) to the mitral annulus between the mitral
valve leaflets (35). The PWD interrogation beam was
carefully aligned with the direction of mitral flow. Pulmo-
nary venous PWD was attempted in all subjects by placing
a 5-mm PWD sample volume in the right upper pulmonary
vein in the apical four-chamber view. The isovolumic
relaxation time was recorded by placing the sample volume
adjacent to the anterior mitral valve leaflet in the LV
outflow tract in a five-chamber view. The signal was
considered optimal when a clear aortic valve closure click
was observed, as well as the onset of early mitral flow. All
PWD recordings were optimized to maximize the signal on
the screen, eliminate excess gain and minimize wall filters
and were recorded at 100 mm/s; only end-expiratory signals
were analyzed.
Patients were instructed in the performance of the Val-
salva maneuver, which they practiced at least once. Mitral
valve inflow PWD was then recorded during the Valsalva
maneuver. Preload reduction was considered adequate if the
mitral velocities dropped by 20%. The Valsalva maneuver
was repeated up to three times to obtain adequate signals. In
addition, a full clinical echocardiogram was obtained.
M-mode echocardiographic recordings (parasternal long-
axis view) were used to calculate LV size, wall thickness,
mass and fractional shortening. The LV volumes and EF
were measured using Simpson’s biplane method from the
apical four- and two-chamber views. The LA area was
measured in the apical four-chamber view at end-systole.
All images were obtained by specially trained research
sonographers, who had no knowledge of the patients’
clinical details.
Echocardiographic measurements. Triplicate measure-
ments of all variables were made off-line (Nova Microson-
ics, Kodak Eastman) by one observer who was blinded to
Abbreviations and Acronyms
AR  abnormal relaxation
CHF  congestive heart failure
DT  deceleration time
E/A  ratio early to late filling ratio
ECG  electrocardiogram
EF  ejection fraction
LA  left atrium
LV  left ventricle
NYHA  New York Heart Association
PN  pseudonormal
PWD  pulsed wave Doppler
RFP  restrictive filling pattern
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the patients’ clinical details. Measurements were made
according to standard methods and included: 1) two-
dimensional and M-mode echocardiographic measurements
(e.g., LV end-diastolic dimension, LV end-systolic dimen-
sion, LV end-diastolic volume, LV end-systolic volume, LA
area); and 2) Doppler measurements (e.g., mitral valve early
peak filling velocity [E], late peak filling velocity [A], DT of
the mitral E-wave, A-wave duration, isovolumic relaxation
time, pulmonary venous peak systolic velocity, peak diastolic
velocity, atrial reversal velocity, atrial reversal duration). The
following variables were calculated: early to late filling ratio
(E/A), pulmonary venous atrial reversal/mitral atrial rever-
sal, stroke volume and EF.
Patients were excluded if complete mitral Doppler mea-
surements could not be obtained. In total, 19 (14.2%) of the
original study participants were excluded: 13 (9.7%) who
had tachycardia and a fused mitral inflow pattern, as shown
by Doppler echocardiography, and 6 (4.4%) who had a
permanent pacemaker. This left 115 patients (85.8%) in
whom a complete Doppler assessment was possible at
baseline.
Differentiation between diastolic filling patterns. After
the baseline measurements were made, each subject was
classified into one of the following categories of filling
patterns (11,12): normal filling: E/A ratio between 1.0 and
2.0 and DT between 0.14 and 0.23 s; AR: E/A ratio 1.0
and DT0.23 s; PN filling: E/A ratio between 1.0 and 2.0,
but E/A ratio 1.0 and DT 0.23 s with the Valsalva
maneuver and/or pulmonary atrial reversal duration/mitral
A-wave duration ratio 1.2; and RFP: E/A ratio 2.0 and
DT 0.14 s.
Statistical analysis. Comparisons between groups for con-
tinuous, normally distributed variables were made using the
Student t test and analysis of variance, as appropriate.
Nonparametric continuous data were analyzed using the
Wilcoxon or Kruskall-Wallis test, as appropriate. Differ-
ences between categorical variables were assessed using the
chi-square test. Stratified survival analysis (time to first
event: death, admission or death and/or re-admission) was
performed using the Kaplan-Meier method. In the multi-
variate analysis, Cox proportional hazards model was used
to adjust for the potential confounding effect of co-variates,
including age and LVEF. All tests were two-tailed, and a
5% significance level was maintained throughout. Proce-
dures of the statistical analysis system SAS were employed
(SAS Institute, Cary, North Carolina).
RESULTS
Patients. One hundred and fifteen patients were followed
up for 12 months (average duration of follow-up: 0.87 
0.28 years). The mean age at study entry was 73  10.8
years. Three quarters of the patients were classified as being
in NYHA functional class IV on hospital admission, but all
patients improved sufficiently to be discharged. The cause
of CHF was considered to be ischemic heart disease in
54% of patients, and the remainder was classified as non-
ischemic, although many of these patients had multiple
potential causes of CHF, with the exact cause often uncer-
tain. Of all patients, 46% had a documented prior myocar-
dial infarction, 52% had previous hypertension and 29% had
diabetes; 52% had a previous admission for CHF before the
index admission. Most were receiving furosemide, and 88%
were receiving an angiotensin-converting enzyme inhibitor.
The average LVEF was 32  13%. In 90% of patients,
LVEF was50%, and in 77% it was40%. Renal function
was impaired, with average creatinine clearance 48.9 
24 ml/min (normal range 90 to 140 ml/min).
Mitral filling pattern. No patients had a normal filling
pattern; 46 (40%) were classified as having AR, 42 (37%) as
PN filling and the remaining 27 (24%) as RFP (Table 1).
There were no statistically significant differences in age,
previous CHF admissions, heart rate, sodium, creatinine,
creatinine clearance or angiotensin-converting enzyme in-
hibitor dose between the three groups. When comparing
the AR group with the PN group, the LA area was smaller,
the E/A ratio was lower and the deceleration and isovolumic
relaxation times were longer. When comparing the AR
group with the RFP group, the systolic and diastolic blood
pressures were higher, the furosemide dose was lower, the
LA area was smaller, the E/A ratio was lower and the
deceleration and isovolumic relaxation times were longer
(Table 1). The mitral A-wave duration time was longer, but
the pulmonary atrial reversal duration was not. When
comparing the PN group with the RFP group, both systolic
and diastolic blood pressures were higher, the E/A ratio was
higher and the DT was prolonged (Table 1). Figure 1
summarizes the flow of patients in the study and shows the
exclusions (14%) and final mitral filling classification based
on the full PWD measurements and events in each group.
Hospital admission. Seventy-six patients (66%) were hos-
pitalized. Re-admission rates were similar between the
non-RFP group (57 re-admissions [65%]) and the RFP
group (19 re-admissions [70%], p  0.48). In the non-RFP
group, there was a significant difference between those with
AR (25 events [54%]) and those with PN filling (32
re-admissions [76%], p  0.0057), as well as a trend
between the AR and RFP groups (19 re-admissions [70%],
p  0.073), but there was no difference between the PN
group (32 re-admissions [76%]) and the RFP group (19
re-admissions [70%], p  0.52) (Fig. 2).
Of the 76 first re-admissions, 31 (41%) were for worsen-
ing CHF. Admissions for worsening CHF were higher in
the RFP group (11 CHF admissions [41%]) than in the
non-RFP group (20 CHF admissions [23%], p 0.046). In
the non-RFP group, those with AR (7 CHF admissions
[15%]) had fewer CHF admissions than those with RFP
(11 CHF admissions [41%], p  0.011), but the non-RFP
group was not statistically different from the PN group (13
CHF admissions [31%], p  0.078). The CHF admissions
were not different between the PN group (13 CHF admis-
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sions [31%]) and the RFP group (11 CHF admissions
[41%], p  0.35) (Fig. 2).
All-cause mortality. In total, there were 28 deaths
(24.3%). Mortality was significantly different between the
non-RFP group (18 deaths [21%]) and the RFP group (10
deaths [37%], p 0.035). In the non-RFP group, mortality
was lower in those with AR (8 deaths [17%]), compared
with the RFP group (10 deaths [37%], p  0.033), but it
was not different from that in the PN group (10 deaths
[24%], p  0.47). Survival in the PN group (10 deaths
Table 1. Clinical and Echocardiographic Variables at the Time of Discharge From the Hospital,
After Stabilization With Medication (n  115)
Variables
Abnormal Relaxation
(n  46)
Pseudonormal Filling
(n  42)
Restrictive Filling
(n  27)
Age (yrs) 73.5  11.4 71.8  9.8 69.6  13.2
NYHA functional class 1.7  0.6 1.9  0.5 2.0  0.6
Previous infarction 24 (52%) 21 (51%) 13 (48%)
No. of previous admissions 1.1  1.4 1.3  1.8 1.3  1.7
Heart rate (beats/min) 82.1  13.2 78.2  11.1 80.1  11.1
Systolic BP (mm Hg) 130.5  22.7 128.0  19.2 113.4  19.3*†
Diastolic BP (mm Hg) 71.8  10.5 74.2  12.2 63.7  10.7*†
Plasma sodium (mmol/l) 138.8  3.5 139.2  3.7 137.6  6.9
Plasma creatinine (mmol/l) 0.12  0.03 0.13  0.05 0.14  0.06
Creatinine clearance (ml/min) 49.6  29.9 49.6  19.8 49.2  25.6
Furosemide (mg) 87.1  62.1 112.2  86.7 155.6  73.9*
ACE inhibitor (mg/day) 9.4  5.8 11.1  6.6 10.6  6.8
LVEDV (ml) 165.6  71.8 181.0  62.4 206.4  83.2
LVESV (ml) 117.1  66.2 125.9  57.3 154.5  75.4
LVEF (%) 32.8  13.6 32.0  11.4 28.7  12.5
LA area (cm2) 24.3  5.0 28.2  4.3‡ 28.2  5.8*
E/A ratio 0.7  0.15 1.3  0.3‡ 2.5  0.8*†
Deceleration time (s) 0.269  0.103 0.191  0.053‡ 0.132  0.038*†
A-wave duration (s) 0.164  0.024 0.153  0.025 0.140  0.024*
Atrial reversal duration (s) 0.131  0.024 0.155  0.33 0.146  0.037
Isovolumic relaxation time (s) 0.073  0.022 0.059  0.017‡ 0.053  0.022*
*p 0.05 for abnormal relaxation versus restrictive filling. †p 0.05 for pseudonormal filling versus restrictive filling. ‡p 0.05
for abnormal relaxation versus pseudonormal filling. Data are presented as the mean value  SD or number (%) of patients.
ACE  angiotensin converting enzyme; BP  blood pressure; E/A ratio  ratio of early passive to late active mitral filling:
LA  left atrium; LVEDV  left ventricular end-diastolic volume; LVESV  left ventricular end-systolic volume; LVEF 
left ventricular ejection fraction; NYHA  New York Heart Association.
Figure 1. Flow chart of patients and events according to inclusion/exclusion criteria and final mitral filling pattern classification. CHF  congestive heart
failure; readm  readmssion.
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[24%]) was not statistically different from that in the RFP
group (10 deaths [37%], p  0.15) (Fig. 3).
All-cause mortality and hospital admission. Eighty pa-
tients (70%) either died or were admitted to the hospital for
any cause. There was no difference between the non-RFP
group (59 events [67%]) and the RFP group (21 events
[78%], p  0.23) for the combined end point of death
and/or hospital admission. However, in the non-RFP
group, there was a significant difference between those with
AR (26 events [57%]) and PN filling (33 events [79%], p 
0.004) and RFP (21 events [78%], p  0.02), but there was
no difference between the PN (33 events [79%]) and RFP
groups (21 events [78%], p  0.78) (Fig. 3).
Fifty-nine patients (51%) either died or were admitted to
the hospital for worsening CHF. There was a significant
difference between the non-RFP (32 events [36%]) and
RFP groups (17 events [63%], p  0.0044) for the com-
bined end point of death and/or CHF re-admission. In the
non-RFP group, there was a significant difference between
those with AR (12 events [26.1%]) and PN filling (20 events
[48%], p  0.03) and RFP (17 events [63%], p  0.0005),
but there was no difference between the PN (20 events
[48%]) and RFP groups (17 events [63%], p  0.15) (Fig.
3).
In the first three months after hospital discharge, there
were 12 deaths (10%) and 47 re-admissions (41%). When
comparing the non-RFP and RFP groups, there was a
significant difference in early mortality (5 [6%] vs. 7 [26%],
p  0.0035) (Fig. 3), but no difference in re-admissions (34
[39%] vs. 13 [48%], p  0.42) (Fig. 2) or the combined end
point of death and/or re-admission (34 [39%] vs. 14 [52%],
p 0.27) (Fig. 3). However, when the non-RFP group was
further classified into PN filling and AR, the AR subgroup
(11 admissions [24%]) had fewer re-admissions than the PN
subgroup (23 admissions [55%], p  0.004) or the RFP
group (13 admissions [48%], p  0.02), and the PN
subgroup (23 admissions [55%]) was not different from the
RFP group (13 admissions [48%], p  0.78) (Fig. 2).
Figure 2. Event-free survival plots for all-cause and congestive heart failure (CHF) hospital admissions; time to first event analysis by the Kaplan-Meier
method. AR  abnormal relaxation; PN  pseudonormal; RFP  restrictive filling pattern.
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DISCUSSION
Patients with LV dysfunction and CHF have a very poor
prognosis (1,2) and frequent hospital re-admissions (36).
End-systolic volume (6) and LVEF (4) are both very useful
echocardiographic measurements for predicting survival in
patients with CHF. However, once severe LV dysfunction is
established, further prognostic differentiation is difficult. Pre-
vious work in this area has highlighted the need to differentiate
those patients with an RFP from those with a non-RFP, as the
former is associated with poor survival (9–13,25–27) and
higher hospital admissions in patients with CHF (37).
Figure 3. Event-free survival plots for all-cause death and hospital admissions; time to first event analysis by the Kaplan-Meier method. AR  abnormal
relaxation; CHF  congestive heart failure; PN  pseudonormal; RFP  restrictive filling pattern.
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This is the first study to demonstrate that using a preload
reduction to differentiate non-RFP provides additional
prognostic information. In particular, the time to first
re-admission in patients with PN filling was comparable to
that observed in patients with RFP, and both were higher
than that observed in patients with an AR pattern. Mortal-
ity was higher in patients with PN filling, and was inter-
mediate between that observed in the AR and RFP groups,
although not statistically different from either, which prob-
ably reflects the small number of events in each group.
However, the PN group had hospital re-admission rates as
high as those observed in patients with RFP, and both were
nearly double that observed in the AR group. Nearly
two-thirds of the re-admissions occurred in the first three
months after the index admission in the RFP and PN
groups, compared with approximately one-fourth in the AR
group. These data suggest that further differentiation of
patients with CHF who have a non-RFP pattern provides
both short- and intermediate-term prognostic information.
Dini et al. (9) used contrast-enhanced pulmonary venous
PWD to differentiate patients with non-RFP. Patients were
not specifically identified as having AR or PN filling, but
the difference between pulmonary venous atrial reversal
duration and mitral A-wave duration was an independent
predictor of cardiac death or worsening heart failure in the
whole group. A longer difference, which is associated with a
higher LA pressure, was associated with higher cardiac
mortality (9). However, pulmonary venous PWD can be
difficult from a transthoracic approach; the preload reduc-
tion method in the current study is much easier to apply.
Despite an older, heterogeneous CHF population, the
current study demonstrated better survival in the non-RFP
group compared with the RFP group, in keeping with many
other published studies (9,11–13). In a larger study of
patients with CHF, similar differences between non-RFP
and RFP were seen for total mortality, CHF hospital
admission and death and/or CHF admission and short DT,
such as might be seen with RFP, the best single predictor of
outcome (11). However, differentiation into AR or PN
filling was not possible, as the study was conducted before
the introduction of contemporary echocardiographic meth-
ods. Our data are in agreement with this study (11), but
extend the findings by further differentiating the non-RFP
group, in particular.
Mitral filling pattern and LA pressure. The mitral valve
E/A ratio and DT are closely associated with mean LA
pressure in patients with systolic dysfunction (38,39). In
patients with chronic CHF and severely impaired LV
function, DT is the best predictor of pulmonary artery
wedge pressure (40). It also provides important prognostic
information in addition to clinical variables, especially when
used to differentiate patients on the basis of RFP and
non-RFP (10–12,25,41). The RFP is correlated with
NYHA functional class (42) and may be the single best
predictor of cardiac death in patients with dilated cardio-
myopathy (12). Recently, in patients with ischemic cardio-
myopathy, a prolonged DT was shown to be related to
myocardial viability and to predict improvement in LVEF
after revascularization (43). Thus, DT is important for
differentiating RFP from non-RFP, but, to date, it has not
been useful for further differentiation and risk stratification
of the subgroups within the non-RFP group. Identification
of RFP by echocardiography appears to be a surrogate for
mean LA or LV end-diastolic pressure (20,38–40), and
categorizing patients on the basis of the mitral filling pattern
identifies subgroups with a progressively higher pressure.
Thus, it follows that if a patient with PN filling has a higher
LA pressure, higher event rates may be anticipated.
Generalizability of results. This study included a mixed
population of patients admitted to the hospital for exacer-
bation of CHF symptoms and are representative of those
patients in a general hospital setting. Other similar studies
often included younger patients, referred for evaluation of
heart transplantation, usually with severely impaired systolic
function (10,11,13,25–27). These differences are reflected in
the high event rate in our study. Because of the nature of the
study, patients with tachycardia, atrial fibrillation or im-
plantable pacemakers were excluded from this analysis; thus,
these results may have limited generalizability in those
groups.
Study limitations. Many patients with CHF have func-
tional mitral regurgitation, so we included them in this
study. Three patients with severe valve disease requiring
surgical intervention were excluded from this study. Some
previous studies have excluded patients on the basis of
significant mitral regurgitation, as it might lead to mislead-
ing results (10,20,33). However, in one study of patients
with dilated cardiomyopathy (both ischemic and nonisch-
emic), an excellent correlation between mitral DT and
pulmonary venous recordings was observed, even in patients
with significant mitral regurgitation (40).
Invasive measurements of the LA pressure would have
confirmed the hypothesis that these findings reflect an
incrementally higher LA pressure in each group. However,
we believe there is considerable experimental data to support
the hypothesis that PN filling is associated with a higher LA
pressure and, likewise, RFP.
A further limitation is the use of the mitral filling pattern
for assessment of diastolic filling, which is affected by heart
rate, loading conditions and age. Heart rate was not signif-
icantly different between the groups. Cardiovascular medi-
cations may affect loading conditions, but all of the patients
were receiving optimal medical therapy and had been
stabilized in the hospital before study entry. Thus, it is
unlikely that major alterations in preload would have af-
fected our results. Angiotensin-converting enzyme inhibi-
tion was similar between the groups, as was beta-blocker
use. Use of diuretics was incrementally higher in each of the
groups: PN filling was higher than AR, and, likewise, RFP
was higher than PN filling. If anything, the greater use of
diuretics would have tended to lower the LA pressure in
those groups, and probably reflects the higher symptomatic
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status of those patients. Tissue Doppler imaging and, in
particular, the ratio of the mitral inflow E velocity to the
mitral annular velocity may have shown similar results and
would potentially be a more powerful continuous variable. It
also may be useful in patients with atrial fibrillation, who
are, by necessity, excluded from the methods used in the
current study.
Conclusions. This study extends the existing data on the
relationship between the mitral filling pattern and death or
hospital admission in patients with CHF. In particular, PN
filling was associated with re-admission rates comparable to
those observed in the RFP group, and death and/or hospital
admission was similar to that observed with RFP and AR.
The current approach, using a preload reduction, is rela-
tively easy to add to routine clinical echocardiography and
may provide important prognostic information in a wide
range of patients with CHF, who might otherwise have
been overlooked. Whether the mitral filling pattern can be
used to guide the management of patients with CHF to
improve long-term outcome remains uncertain.
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